Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization

Human Pathology

Volumn 45, Issue 4, 2014, Pages 725-734

  Tajiri, Ryosuke ^a   Ooi, Akishi ^a   Fujimura, Takashi ^a   Dobashi, Yoh ^b   Oyama, Takeru ^a   Nakamura, Ritsuko ^a   Ikeda, Hiroko ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

ERBB2; FISH; Gastric cancer; Gene amplification; HER2; MLPA

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR 10; FIBROBLAST GROWTH FACTOR RECEPTOR 2; MYC PROTEIN; PROTEIN MDM2; SCATTER FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR;

AMPLICON; ARTICLE; CANCER CELL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; STOMACH CANCER; CANCER STAGING; CELL POPULATION; CONTROLLED STUDY; DOUBLE MINUTE CHROMOSOME; HUMAN TISSUE; STOMACH ADENOCARCINOMA;

ERBB2; FISH; GASTRIC CANCER; GENE AMPLIFICATION; HER2; MLPA;

ADENOCARCINOMA; GENE AMPLIFICATION; GENES, ERBB-2; GENES, MYC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MULTIPLEX POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84896548329     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2013.11.004     Document Type: Article

References (30)

1. J. Ferlay, D.M. Parkin, and E. Steliarova-Foucher Estimates of cancer incidence and mortality in Europe in 2008 Eur J Cancer 46 2010 765 781
2. Japanese Research Society for Gastric Cancer Committee on Histologic Classification of Gastric Cancer The general rules for the gastric cancer Jpn J Surg 11 1981 140 145
3. T. Okabayashi, M. Kobayashi, and I. Nishimori et al. Clinicopathological features and medical management of early gastric cancer Am J Surg 195 2008 229 232
4. J.W. Fielding, C. Roginski, and D.J. Ellis et al. Clinicopathological staging of gastric cancer Br J Surg 71 1984 677 680 (Pubitemid 14066669)
5. A. Okines, D. Cunningham, and I. Chau Targeting the human EGFR family in esophagogastric cancer Nat Rev Clin Oncol 8 2011 492 503
6. L. Fornaro, M. Lucchesi, and C. Caparello et al. Anti-HER agents in gastric cancer: from bench to bedside Nat Rev Gastroenterol Hepatol 8 2011 369 383
7. J. Ruschoff, W. Hanna, and M. Bilous et al. HER2 testing in gastric cancer: a practical approach Mod Pathol 25 2012 637 650
8. A.F. Okines, and D. Cunningham Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer Ther Adv Gastroenterol 5 2012 301 318
9. S.Y. Kanta, T. Yamane, Y. Dobashi, F. Mitsui, K. Kono, and A. Ooi Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study Hum Pathol 37 2006 1333 1343 (Pubitemid 44380283)
10. T. Takehana, K. Kunitomo, and K. Kono et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay Int J Cancer 98 2002 833 837 (Pubitemid 34286677)
11. T. Yano, T. Doi, and A. Ohtsu et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer Oncol Rep 15 2006 65 71
12. C.A. Hudis Trastuzumab - mechanism of action and use in clinical practice N Engl J Med 357 2007 39 51 (Pubitemid 47026733)
13. Y.J. Bang, E. Van Cutsem, and A. Feyereislova et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 2010 687 697
14. N. Deng, L.K. Goh, and H. Wang et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets Gut 61 2012 673 684
15. E. Rossi, C. Klersy, R. Manca, O. Zuffardi, and E. Solcia Correlation between genomic alterations assessed by array comparative genomic hybridization, prognostically informative histologic subtype, stage, and patient survival in gastric cancer Hum Pathol 42 2011 1937 1945
16. A. Marusyk, V. Almendro, and K. Polyak Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 12 2012 323 334
17. K. Kunitomo, S. Inoue, and F. Ichihara et al. A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel Hum Pathol 35 2004 379 381 (Pubitemid 38339615)
18. D.J. Bunyan, D.M. Eccles, and J. Sillibourne et al. Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification Br J Cancer 91 2004 1155 1159 (Pubitemid 39336256)
19. A. Ooi, M. Inokuchi, and S. Harada et al. Gene amplification of ESR1 in breast cancers-fact or fiction? A fluorescence in situ hybridization and multiplex ligation-dependent probe amplification study J Pathol 227 2012 8 16
20. AJCC Stomach S.B. Edge, D.R. Byrd, C.C. Compton, A.G. Fritz, F.L. Greene, and A. Trotti III AJCC cancer staging manual 7th ed 2010 Springer New York, NY 117 120
21. C. Fenoglio-Preiser, N. Muroz, and F. Carneiro et al. Tumours of the stomach S.R. Hamilton, L.A. Aaltonen, World Health Organization Classification of Tumours. Tumours of the digestive system 2000 IARC Press Lyon, France 37 66
22. A.C. Wolff, M.E. Hammond, and J.N. Schwartz et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 2007 118 145 (Pubitemid 350003059)
23. T. Takehana, K. Kunitomo, and S. Suzuki et al. Expression of epidermal growth factor receptor in gastric carcinomas Clin Gastroenterol Hepatol 1 2003 438 445 (Pubitemid 37413607)
24. T. Hara, A. Ooi, and M. Kobayashi et al. Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization Lab Invest 78 1998 1143 1153 (Pubitemid 28440830)
25. M. Kobayashi, A. Ooi, Y. Oda, and I. Nakanishi Protein overexpression and gene amplification of c-erbB-2 in breast carcinomas: a comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissues Hum Pathol 33 2002 21 28 (Pubitemid 34112949)
26. J.K. Lennerz, E.L. Kwak, and A. Ackerman et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib J Clin Oncol 29 2011 4803 4810
27. M. Fralick, J.F. Hilton, N. Bouganim, M. Clemons, and E. Amir Dual blockade of HER2 - twice as good or twice as toxic? Clin Oncol (R Coll Radiol) 24 2012 593 603
28. C. Kim, J. Bryant, and Z. Horne et al. Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMyc in vivo Breast Cancer Res Treat 54 Suppl 1 2005 S6 (abstract)
29. K. Kunii, L. Davis, and J. Gorenstein et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival Cancer Res 68 2008 2340 2348 (Pubitemid 351521808)
30. A. Di Leo, D. Gancberg, and D. Larsimont et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil Clin Cancer Res 8 2002 1107 1116 (Pubitemid 34517647)